|  |  |
| --- | --- |
| **Name, Surname**: Güzin FİDAN YAYLALI |  |
| **Date of Birth:** 21.11 1974**Affiliation:** Pamukkale University Faculty of Medicine*,* Department of Endocrinology and Metabolism**Academic Degree:** Assistant Professor |

**1. PERSONAL INFORMATION**

2. **EDUCATION**

|  |  |  |  |
| --- | --- | --- | --- |
| YEAR |  | UNIVERSITY | SPECIALTY |
| 1991-1998 | Medical School | Hacettepe University, Faculty of Medicine  |  |
| 1999-2003 | Residency | Pamukkale University  | Internal Medicine |
| 2004-2009 | Residency | Pamukkale University  | Endocrinology and Metabolic Diseases  |

**3. ACADEMIC EXPERIENCE**

|  |  |  |  |
| --- | --- | --- | --- |
| YEAR | POSITION | DEPARTMENT | UNIVERSITY |
| 2012-2017 | Asst.Prof. | Endocrinology and Metabolic Diseases | Pamukkale University |
| 2017- | Prof Dr | Endocrinology and Metabolic Diseases | Pamukkale University |

**4. PUBLICATIONS**

1. Haymana C, Sonmez A, Demirci I, **Fidan Yaylalı G**, Nuhoglu I, Sancak S, Yilmaz M, Altuntas Y, Dinccag N, Sabuncu T, Bayram F, Satman I; TEMD Study Group[**Patterns and preferences of antidiabetic drug use in Turkish patients with type 2 diabetes - A nationwide cross-sectional study (TEMD treatment study).**](https://pubmed.ncbi.nlm.nih.gov/33242516/)

.Diabetes Res Clin Pract. 2020 Nov 24;171:108556. doi: 10.1016/j.diabres.2020.108556. Online ahead of print.

1. Sonmez A, Tasci I, Demirci I, Haymana C, Barcin C, Aydin H, Cetinkalp S, Ozturk FY, Gul K, Sabuncu T, Satman I, Bayram F; **TEMD Study Group.** [**A Cross-Sectional Study of Overtreatment and Deintensification of Antidiabetic and Antihypertensive Medications in Diabetes Mellitus: The TEMD Overtreatment Study.**](https://pubmed.ncbi.nlm.nih.gov/32088879/).Diabetes Ther. 2020 May;11(5):1045-1059. doi: 10.1007/s13300-020-00779-0. Epub 2020 Feb 22.PMID: 32088879
2. Sabuncu T, Sonmez A, Eren MA, Sahin I, Çorapçioğlu D, Üçler R, Akin Ş, Haymana C, Demirci İ, Atmaca A, Ersöz HÖ, Satman I, Bayram F; **TEMD Study Group** [**Characteristics of patients with hypertension in a population with type 2 diabetes mellitus. Results from the Turkish Nationwide SurvEy of Glycemic and Other Metabolic Parameters of Patients with Diabetes Mellitus (TEMD Hypertension Study).**](https://pubmed.ncbi.nlm.nih.gov/33277201/) Prim Care Diabetes. 2020 Dec 1:S1751-9918(20)30313-2. doi: 10.1016/j.pcd.2020.11.001. Online ahead of print.PMID: 33277201
3. Bayram F, Sonmez A, Haymana C, Sabuncu T, Dizdar OS, Gurkan E, Carlioglu AK, Agbaht K, Ozdemir D, Demirci I, Barcin C, Salman S, Tetiker T, Balci MK, Kebapci N, Ersoy C, Yumuk V, Toth PP, Satman I; **TEMD Study Group** [**Utilization of statins and LDL-cholesterol target attainment in Turkish patients with type 2 diabetes - a nationwide cross-sectional study (TEMD dyslipidemia study).**](https://pubmed.ncbi.nlm.nih.gov/33176832/)Lipids Health Dis. 2020 Nov 11;19(1):237. doi: 10.1186/s12944-020-01408-2.
4. Keskin Ç, Demir Ö, Karcı AÇ, Berker D, Cantürk Z, **Yaylali GF**, Topsakal Ş, Ersoy R, Bayram F, Ertörer ME, Bozkırlı E, Haydardedeoğlu F, Dilekçi ENA, Ay SA, Cansu GB, Şahin M, Emral R, Çorapçıoğlu D. [**The acromegaly registry of ten different centers in Turkey.**](https://pubmed.ncbi.nlm.nih.gov/32417639/)Growth Horm IGF Res. 2020 Aug-Oct;53-54:101322. doi: 10.1016/j.ghir.2020.101322. Epub 2020 Apr 27.PMID: 32417639
5. Atıgan A, Ardıç F,Fındıkoğlu G,Aybek H ,**Fidan Yaylalı G**. **Similar effects of three endurance exercise protocols in women with metabolic syndrome: Interest of moderate-intensity aerobic exercise training with a pedometer.** August 2020 [Science & Sports](https://www.researchgate.net/journal/0765-1597_Science_Sports) DOI: [10.1016/j.scispo.2020.03.008](https://www.researchgate.net/deref/http%3A//dx.doi.org/10.1016/j.scispo.2020.03.008)
6. Burcu Yapar Taskoylu, **Guzin Fidan Yaylali**, Gamze Gokoz Dogu, Atike Gokcen Demiray, Serkan Degirmencioglu, Ahmet Ergin, Arzu Yaren**.**[**Effects of Megestrol Acetate on Adrenal Function and Survival in Cancer Patients**](https://www.ejmo.org/10.14744/ejmo.2019.37124/)**.** EJMO 2019;3(3):199–202 DOI: 10.14744/ejmo.2019.37124
7. Burcu Yapar Taskoylu, Fenkci S,Oztekin O, Enli Y, Topsakal S, **Fidan Yaylali G. How to Effect of Metformin Adding to Cyproterone Acetate+Ethinyl Estradiol Treatment on Antioxidant Status in Polycystıc Ovary Syndrome?** EJMI 2019;3(1):14–18 DOI: 10.14744/ejmi.2018.92400
8. Toprak I, Fenkci SM, **Fidan Yaylali G**, Martin C, Yaylali V. [**Early retinal neurodegeneration in preclinical diabetic retinopathy: a multifactorial investigation.**](https://www.ncbi.nlm.nih.gov/pubmed/31654034) Eye (Lond). 2020  Jun;34(6):1100-1107. doi: 10.1038/s41433-019-0646-1
9. Toprak I, Fenkci SM, **Fidan Yaylali G**, Martin C, Yaylali V. [**Effect of microalbuminuria on corneal endothelium in patients with diabetes without retinopathy.**](https://www.ncbi.nlm.nih.gov/pubmed/31625203) Clin Exp Optom. 2020 Sep;103(5):625-629. Oct 17. doi: 10.1111/cxo.12969.
10. [Sonmez A](https://www.ncbi.nlm.nih.gov/pubmed/?term=Sonmez%20A%5BAuthor%5D&cauthor=true&cauthor_uid=30893706)1, [Yumuk V](https://www.ncbi.nlm.nih.gov/pubmed/?term=Yumuk%20V%5BAuthor%5D&cauthor=true&cauthor_uid=30893706)2, [Haymana C](https://www.ncbi.nlm.nih.gov/pubmed/?term=Haymana%20C%5BAuthor%5D&cauthor=true&cauthor_uid=30893706)3, [Demirci I](https://www.ncbi.nlm.nih.gov/pubmed/?term=Demirci%20I%5BAuthor%5D&cauthor=true&cauthor_uid=30893706)3, [Barcin C](https://www.ncbi.nlm.nih.gov/pubmed/?term=Barcin%20C%5BAuthor%5D&cauthor=true&cauthor_uid=30893706)4, [Kıyıcı S](https://www.ncbi.nlm.nih.gov/pubmed/?term=K%C4%B1y%C4%B1c%C4%B1%20S%5BAuthor%5D&cauthor=true&cauthor_uid=30893706)5, [Güldiken S](https://www.ncbi.nlm.nih.gov/pubmed/?term=G%C3%BCldiken%20S%5BAuthor%5D&cauthor=true&cauthor_uid=30893706)6, [Örük G](https://www.ncbi.nlm.nih.gov/pubmed/?term=%C3%96r%C3%BCk%20G%5BAuthor%5D&cauthor=true&cauthor_uid=30893706)7, [Ozgen Saydam B](https://www.ncbi.nlm.nih.gov/pubmed/?term=Ozgen%20Saydam%20B%5BAuthor%5D&cauthor=true&cauthor_uid=30893706)8, [Baldane S](https://www.ncbi.nlm.nih.gov/pubmed/?term=Baldane%20S%5BAuthor%5D&cauthor=true&cauthor_uid=30893706)9, [Kutlutürk F](https://www.ncbi.nlm.nih.gov/pubmed/?term=Kutlut%C3%BCrk%20F%5BAuthor%5D&cauthor=true&cauthor_uid=30893706)10, [Küçükler FK](https://www.ncbi.nlm.nih.gov/pubmed/?term=K%C3%BC%C3%A7%C3%BCkler%20FK%5BAuthor%5D&cauthor=true&cauthor_uid=30893706)11, [Deyneli O](https://www.ncbi.nlm.nih.gov/pubmed/?term=Deyneli%20O%5BAuthor%5D&cauthor=true&cauthor_uid=30893706)12, [Çetinarslan B](https://www.ncbi.nlm.nih.gov/pubmed/?term=%C3%87etinarslan%20B%5BAuthor%5D&cauthor=true&cauthor_uid=30893706)13, [Sabuncu T](https://www.ncbi.nlm.nih.gov/pubmed/?term=Sabuncu%20T%5BAuthor%5D&cauthor=true&cauthor_uid=30893706)14, [Bayram F](https://www.ncbi.nlm.nih.gov/pubmed/?term=Bayram%20F%5BAuthor%5D&cauthor=true&cauthor_uid=30893706)15, [Satman I](https://www.ncbi.nlm.nih.gov/pubmed/?term=Satman%20I%5BAuthor%5D&cauthor=true&cauthor_uid=30893706)16; [**TEMD Study Group**](https://www.ncbi.nlm.nih.gov/pubmed/?term=TEMD%C2%A0Study%C2%A0Group%5BCorporate%20Author%5D).

Impact of Obesity on the Metabolic Control of Type 2 Diabetes: Results of the Turkish Nationwide Survey of Glycemic and Other Metabolic Parameters of Patients with Diabetes Mellitus (TEMD Obesity Study). [Obes Facts.](https://www.ncbi.nlm.nih.gov/pubmed/?term=Impact+of+Obesity+on+the+Metabolic+Control+of+Type+2+Diabetes%3A+Results+of+the+Turkish+Nationwide+Survey+of+Glycemic+and+Other+Metabolic+Parameters+of+Patients+with+Diabetes+Mellitus+(TEMD+Obesity+Study)) 2019;12(2):167-178. doi: 10.1159/000496624. Epub 2019 Mar 20.

TEMD STUDY GROUP: [Guldiken S](https://www.ncbi.nlm.nih.gov/pubmed/?term=Guldiken%20S)11, [Ayturk S](https://www.ncbi.nlm.nih.gov/pubmed/?term=Ayturk%20S)11, [Yilmaz M](https://www.ncbi.nlm.nih.gov/pubmed/?term=Yilmaz%20M)12, [Asik M](https://www.ncbi.nlm.nih.gov/pubmed/?term=Asik%20M)13, [Dinccag N](https://www.ncbi.nlm.nih.gov/pubmed/?term=Dinccag%20N)14, [Cakmak R](https://www.ncbi.nlm.nih.gov/pubmed/?term=Cakmak%20R)14, [Turker F](https://www.ncbi.nlm.nih.gov/pubmed/?term=Turker%20F)14, [Idiz C](https://www.ncbi.nlm.nih.gov/pubmed/?term=Idiz%20C)14, [Hacisahinogullari H](https://www.ncbi.nlm.nih.gov/pubmed/?term=Hacisahinogullari%20H)14, [Bagdemir E](https://www.ncbi.nlm.nih.gov/pubmed/?term=Bagdemir%20E)14, [Yildiz B](https://www.ncbi.nlm.nih.gov/pubmed/?term=Yildiz%20B)14, [Yumuk VD](https://www.ncbi.nlm.nih.gov/pubmed/?term=Yumuk%20VD)15, [Haliloglu O](https://www.ncbi.nlm.nih.gov/pubmed/?term=Haliloglu%20O)15, [Sancak S](https://www.ncbi.nlm.nih.gov/pubmed/?term=Sancak%20S)16, [Ozsari L](https://www.ncbi.nlm.nih.gov/pubmed/?term=Ozsari%20L)17, [Cagiltay E](https://www.ncbi.nlm.nih.gov/pubmed/?term=Cagiltay%20E)17, [Deyneli O](https://www.ncbi.nlm.nih.gov/pubmed/?term=Deyneli%20O)18, [Imre E](https://www.ncbi.nlm.nih.gov/pubmed/?term=Imre%20E)18, [Gonen S](https://www.ncbi.nlm.nih.gov/pubmed/?term=Gonen%20S)19, [Boysan SN](https://www.ncbi.nlm.nih.gov/pubmed/?term=Boysan%20SN)19, [Altuntas Y](https://www.ncbi.nlm.nih.gov/pubmed/?term=Altuntas%20Y)20, [Ozturk FY](https://www.ncbi.nlm.nih.gov/pubmed/?term=Ozturk%20FY)20, [Mert M](https://www.ncbi.nlm.nih.gov/pubmed/?term=Mert%20M)21, [Piskinpasa H](https://www.ncbi.nlm.nih.gov/pubmed/?term=Piskinpasa%20H)21, [Aydin H](https://www.ncbi.nlm.nih.gov/pubmed/?term=Aydin%20H)22, [Imamoglu S](https://www.ncbi.nlm.nih.gov/pubmed/?term=Imamoglu%20S)23, [Ersoy C](https://www.ncbi.nlm.nih.gov/pubmed/?term=Ersoy%20C)24, [Gul OO](https://www.ncbi.nlm.nih.gov/pubmed/?term=Gul%20OO)24, [Kucuksarac Kiyici S](https://www.ncbi.nlm.nih.gov/pubmed/?term=Kucuksarac%20Kiyici%20S)25, [Cetinarslan B](https://www.ncbi.nlm.nih.gov/pubmed/?term=Cetinarslan%20B)26, [Selek A](https://www.ncbi.nlm.nih.gov/pubmed/?term=Selek%20A)26, [Dogru T](https://www.ncbi.nlm.nih.gov/pubmed/?term=Dogru%20T)27, [Kirik A](https://www.ncbi.nlm.nih.gov/pubmed/?term=Kirik%20A)27, [Kebapci N](https://www.ncbi.nlm.nih.gov/pubmed/?term=Kebapci%20N)28, [Efe B](https://www.ncbi.nlm.nih.gov/pubmed/?term=Efe%20B)28, [Kaya A](https://www.ncbi.nlm.nih.gov/pubmed/?term=Kaya%20A)29, [Cordan I](https://www.ncbi.nlm.nih.gov/pubmed/?term=Cordan%20I)29, [Baldane S](https://www.ncbi.nlm.nih.gov/pubmed/?term=Baldane%20S)30, [Kirac CO](https://www.ncbi.nlm.nih.gov/pubmed/?term=Kirac%20CO)30, [Demirci I](https://www.ncbi.nlm.nih.gov/pubmed/?term=Demirci%20I)31, [Capa Z](https://www.ncbi.nlm.nih.gov/pubmed/?term=Capa%20Z)31, [Cesur M](https://www.ncbi.nlm.nih.gov/pubmed/?term=Cesur%20M)32, [Yetkin I](https://www.ncbi.nlm.nih.gov/pubmed/?term=Yetkin%20I)33, [Corapcioglu D](https://www.ncbi.nlm.nih.gov/pubmed/?term=Corapcioglu%20D)34, [Canlar S](https://www.ncbi.nlm.nih.gov/pubmed/?term=Canlar%20S)34, [Bulent Yildiz O](https://www.ncbi.nlm.nih.gov/pubmed/?term=Bulent%20Yildiz%20O)35, [Sendur SN](https://www.ncbi.nlm.nih.gov/pubmed/?term=Sendur%20SN)35, [Cakir B](https://www.ncbi.nlm.nih.gov/pubmed/?term=Cakir%20B)36, [Ozdemir D](https://www.ncbi.nlm.nih.gov/pubmed/?term=Ozdemir%20D)36, [Corakci A](https://www.ncbi.nlm.nih.gov/pubmed/?term=Corakci%20A)37, [Kutlu M](https://www.ncbi.nlm.nih.gov/pubmed/?term=Kutlu%20M)38, [Bascil Tutuncu N](https://www.ncbi.nlm.nih.gov/pubmed/?term=Bascil%20Tutuncu%20N), [Bozkus Y](https://www.ncbi.nlm.nih.gov/pubmed/?term=Bozkus%20Y)39, [Cakal E](https://www.ncbi.nlm.nih.gov/pubmed/?term=Cakal%20E)40, [Demirbas B](https://www.ncbi.nlm.nih.gov/pubmed/?term=Demirbas%20B)41, [Ertek S](https://www.ncbi.nlm.nih.gov/pubmed/?term=Ertek%20S)42, [Altay M](https://www.ncbi.nlm.nih.gov/pubmed/?term=Altay%20M)43, [Dagdeviren M](https://www.ncbi.nlm.nih.gov/pubmed/?term=Dagdeviren%20M)43, [Abedi AH](https://www.ncbi.nlm.nih.gov/pubmed/?term=Abedi%20AH)44, [Cetinkalp S](https://www.ncbi.nlm.nih.gov/pubmed/?term=Cetinkalp%20S)45, [Ozisik H](https://www.ncbi.nlm.nih.gov/pubmed/?term=Ozisik%20H)45, [Oruk GG](https://www.ncbi.nlm.nih.gov/pubmed/?term=Oruk%20GG)46, [Yener S](https://www.ncbi.nlm.nih.gov/pubmed/?term=Yener%20S)47, [Saydam BO](https://www.ncbi.nlm.nih.gov/pubmed/?term=Saydam%20BO)47, [Guney E](https://www.ncbi.nlm.nih.gov/pubmed/?term=Guney%20E)48, [Unubol M](https://www.ncbi.nlm.nih.gov/pubmed/?term=Unubol%20M)48, [**Yaylali GF**](https://www.ncbi.nlm.nih.gov/pubmed/?term=Yaylali%20GF)**49**, [Topsakal S](https://www.ncbi.nlm.nih.gov/pubmed/?term=Topsakal%20S)49, [Hekimsoy Z](https://www.ncbi.nlm.nih.gov/pubmed/?term=Hekimsoy%20Z)50, [Akbaba G](https://www.ncbi.nlm.nih.gov/pubmed/?term=Akbaba%20G)51, [Aslan I](https://www.ncbi.nlm.nih.gov/pubmed/?term=Aslan%20I)52, [Balci MK](https://www.ncbi.nlm.nih.gov/pubmed/?term=Balci%20MK)53, [Dalkiran S](https://www.ncbi.nlm.nih.gov/pubmed/?term=Dalkiran%20S)53, [Akbay E](https://www.ncbi.nlm.nih.gov/pubmed/?term=Akbay%20E)54, [Gul K](https://www.ncbi.nlm.nih.gov/pubmed/?term=Gul%20K)55, [Agbaht K](https://www.ncbi.nlm.nih.gov/pubmed/?term=Agbaht%20K)56, [Yilmaz MO](https://www.ncbi.nlm.nih.gov/pubmed/?term=Yilmaz%20MO)57, [Bozkirli E](https://www.ncbi.nlm.nih.gov/pubmed/?term=Bozkirli%20E)58, [Tetiker BT](https://www.ncbi.nlm.nih.gov/pubmed/?term=Tetiker%20BT)59, [Cetinkaya Altuntas S](https://www.ncbi.nlm.nih.gov/pubmed/?term=Cetinkaya%20Altuntas%20S)59, [Atmaca A](https://www.ncbi.nlm.nih.gov/pubmed/?term=Atmaca%20A)60, [Durmuş ET](https://www.ncbi.nlm.nih.gov/pubmed/?term=Durmu%C5%9F%20ET)60, [Mete T](https://www.ncbi.nlm.nih.gov/pubmed/?term=Mete%20T)61, [Kutluturk F](https://www.ncbi.nlm.nih.gov/pubmed/?term=Kutluturk%20F)62, [Kucukler FK](https://www.ncbi.nlm.nih.gov/pubmed/?term=Kucukler%20FK)63, [Dikbas O](https://www.ncbi.nlm.nih.gov/pubmed/?term=Dikbas%20O)64, [Akin S](https://www.ncbi.nlm.nih.gov/pubmed/?term=Akin%20S)65, [Nuhoglu I](https://www.ncbi.nlm.nih.gov/pubmed/?term=Nuhoglu%20I)66, [Ersoz HO](https://www.ncbi.nlm.nih.gov/pubmed/?term=Ersoz%20HO)66, [Bayraktaroglu T](https://www.ncbi.nlm.nih.gov/pubmed/?term=Bayraktaroglu%20T)67, [Sisman P](https://www.ncbi.nlm.nih.gov/pubmed/?term=Sisman%20P)68, [Sahin I](https://www.ncbi.nlm.nih.gov/pubmed/?term=Sahin%20I)69, [Cetin S](https://www.ncbi.nlm.nih.gov/pubmed/?term=Cetin%20S)69, [Capoglu I](https://www.ncbi.nlm.nih.gov/pubmed/?term=Capoglu%20I)70, [Akbas EM](https://www.ncbi.nlm.nih.gov/pubmed/?term=Akbas%20EM)70, [Ucler R](https://www.ncbi.nlm.nih.gov/pubmed/?term=Ucler%20R)71, [Eren MA](https://www.ncbi.nlm.nih.gov/pubmed/?term=Eren%20MA)72, [Tuzcu AK](https://www.ncbi.nlm.nih.gov/pubmed/?term=Tuzcu%20AK)73, [Pekkolay Z](https://www.ncbi.nlm.nih.gov/pubmed/?term=Pekkolay%20Z)73, [Ozkaya M](https://www.ncbi.nlm.nih.gov/pubmed/?term=Ozkaya%20M)74, [Araz M](https://www.ncbi.nlm.nih.gov/pubmed/?term=Araz%20M)75.

1. Yaylali YT, **Fidan-Yaylali G**, Dedeoglu O, Senol H. [**Osteocalcin and epicardial adipose tissue in obesity: new hints for epicardial adipose tissue-bone crosstalk.**](https://www.ncbi.nlm.nih.gov/pubmed/31455100) Scand Cardiovasc J. 2019 Dec;53(6):296-298. doi: 10.1080/14017431.2019.1659397. Epub 2019 Aug 28.
2. [Aydın H](https://www.ncbi.nlm.nih.gov/pubmed/?term=Ayd%C4%B1n%20H%5BAuthor%5D&cauthor=true&cauthor_uid=30402933), [Çelik Ö](https://www.ncbi.nlm.nih.gov/pubmed/?term=%C3%87elik%20%C3%96%5BAuthor%5D&cauthor=true&cauthor_uid=30402933), [Yazıcı D](https://www.ncbi.nlm.nih.gov/pubmed/?term=Yaz%C4%B1c%C4%B1%20D%5BAuthor%5D&cauthor=true&cauthor_uid=30402933), [Altunok Ç](https://www.ncbi.nlm.nih.gov/pubmed/?term=Altunok%20%C3%87%5BAuthor%5D&cauthor=true&cauthor_uid=30402933), [Tarçın Ö](https://www.ncbi.nlm.nih.gov/pubmed/?term=Tar%C3%A7%C4%B1n%20%C3%96%5BAuthor%5D&cauthor=true&cauthor_uid=30402933), [Deyneli O](https://www.ncbi.nlm.nih.gov/pubmed/?term=Deyneli%20O%5BAuthor%5D&cauthor=true&cauthor_uid=30402933), [Sancak S](https://www.ncbi.nlm.nih.gov/pubmed/?term=Sancak%20S%5BAuthor%5D&cauthor=true&cauthor_uid=30402933), [Kıyıcı S](https://www.ncbi.nlm.nih.gov/pubmed/?term=K%C4%B1y%C4%B1c%C4%B1%20S%5BAuthor%5D&cauthor=true&cauthor_uid=30402933), [Aydın K](https://www.ncbi.nlm.nih.gov/pubmed/?term=Ayd%C4%B1n%20K%5BAuthor%5D&cauthor=true&cauthor_uid=30402933), [Okan Yıldız B](https://www.ncbi.nlm.nih.gov/pubmed/?term=Okan%20Y%C4%B1ld%C4%B1z%20B%5BAuthor%5D&cauthor=true&cauthor_uid=30402933); [**TURGEP Study Group**](https://www.ncbi.nlm.nih.gov/pubmed/?term=TURGEP%20Study%20Group%5BCorporate%20Author%5D)**. Prevalence and predictors of gestational diabetes mellitus: a nationwide multicentre prospective study**. Diabet Med. 2019 Feb;36(2):221-227. doi: 10.1111/dme.13857.

TURGEP STUDY GROUP: [Çakıroğlu AY](https://www.ncbi.nlm.nih.gov/pubmed/?term=%C3%87ak%C4%B1ro%C4%9Flu%20AY), [Özer A](https://www.ncbi.nlm.nih.gov/pubmed/?term=%C3%96zer%20A), [Tuzcu AK](https://www.ncbi.nlm.nih.gov/pubmed/?term=Tuzcu%20AK), [Kan A](https://www.ncbi.nlm.nih.gov/pubmed/?term=Kan%20A), [Çelik A](https://www.ncbi.nlm.nih.gov/pubmed/?term=%C3%87elik%20A), [Uysal A](https://www.ncbi.nlm.nih.gov/pubmed/?term=Uysal%20A), [Atmaca A](https://www.ncbi.nlm.nih.gov/pubmed/?term=Atmaca%20A), [Evren B](https://www.ncbi.nlm.nih.gov/pubmed/?term=Evren%20B), [Taşkıran B](https://www.ncbi.nlm.nih.gov/pubmed/?term=Ta%C5%9Fk%C4%B1ran%20B), [Bilir BE](https://www.ncbi.nlm.nih.gov/pubmed/?term=Bilir%20BE), [Duran C](https://www.ncbi.nlm.nih.gov/pubmed/?term=Duran%20C), [Arpacı D](https://www.ncbi.nlm.nih.gov/pubmed/?term=Arpac%C4%B1%20D), [Tüzün D](https://www.ncbi.nlm.nih.gov/pubmed/?term=T%C3%BCz%C3%BCn%20D), [Kavak EÇ](https://www.ncbi.nlm.nih.gov/pubmed/?term=Kavak%20E%C3%87), [Aydeniz E](https://www.ncbi.nlm.nih.gov/pubmed/?term=Aydeniz%20E), [Akbaş EM](https://www.ncbi.nlm.nih.gov/pubmed/?term=Akba%C5%9F%20EM), [Üstünyurt E](https://www.ncbi.nlm.nih.gov/pubmed/?term=%C3%9Cst%C3%BCnyurt%20E), [Bil E](https://www.ncbi.nlm.nih.gov/pubmed/?term=Bil%20E), [Güney E](https://www.ncbi.nlm.nih.gov/pubmed/?term=G%C3%BCney%20E), [Akbaba E](https://www.ncbi.nlm.nih.gov/pubmed/?term=Akbaba%20E), [Gürkan E](https://www.ncbi.nlm.nih.gov/pubmed/?term=G%C3%BCrkan%20E), [Çağlıyan E](https://www.ncbi.nlm.nih.gov/pubmed/?term=%C3%87a%C4%9Fl%C4%B1yan%20E), [Karakılıç E](https://www.ncbi.nlm.nih.gov/pubmed/?term=Karak%C4%B1l%C4%B1%C3%A7%20E), [Karakaş E](https://www.ncbi.nlm.nih.gov/pubmed/?term=Karaka%C5%9F%20E), [Kılınç F](https://www.ncbi.nlm.nih.gov/pubmed/?term=K%C4%B1l%C4%B1n%C3%A7%20F), [Söylemez F](https://www.ncbi.nlm.nih.gov/pubmed/?term=S%C3%B6ylemez%20F), [Küçükler FK](https://www.ncbi.nlm.nih.gov/pubmed/?term=K%C3%BC%C3%A7%C3%BCkler%20FK), [Yorulmaz G](https://www.ncbi.nlm.nih.gov/pubmed/?term=Yorulmaz%20G), [Akbaba G](https://www.ncbi.nlm.nih.gov/pubmed/?term=Akbaba%20G), [Uysal G](https://www.ncbi.nlm.nih.gov/pubmed/?term=Uysal%20G), [Kurt G](https://www.ncbi.nlm.nih.gov/pubmed/?term=Kurt%20G)**,**[**Yaylalı GF**](https://www.ncbi.nlm.nih.gov/pubmed/?term=Yaylal%C4%B1%20GF), [Selimoğlu H](https://www.ncbi.nlm.nih.gov/pubmed/?term=Selimo%C4%9Flu%20H), [Sarı H](https://www.ncbi.nlm.nih.gov/pubmed/?term=Sar%C4%B1%20H), [Pişkinpaşa H](https://www.ncbi.nlm.nih.gov/pubmed/?term=Pi%C5%9Fkinpa%C5%9Fa%20H), [Çelik H](https://www.ncbi.nlm.nih.gov/pubmed/?term=%C3%87elik%20H), [Peynirci H](https://www.ncbi.nlm.nih.gov/pubmed/?term=Peynirci%20H), [Bilal I](https://www.ncbi.nlm.nih.gov/pubmed/?term=Bilal%20I), [Şahin İ](https://www.ncbi.nlm.nih.gov/pubmed/?term=%C5%9Eahin%20%C4%B0), [Gözükara İ](https://www.ncbi.nlm.nih.gov/pubmed/?term=G%C3%B6z%C3%BCkara%20%C4%B0), [Anaforoğlu İ](https://www.ncbi.nlm.nih.gov/pubmed/?term=Anaforo%C4%9Flu%20%C4%B0), [Şenyuva İ](https://www.ncbi.nlm.nih.gov/pubmed/?term=%C5%9Eenyuva%20%C4%B0), [Uğur K](https://www.ncbi.nlm.nih.gov/pubmed/?term=U%C4%9Fur%20K), [Doğan K](https://www.ncbi.nlm.nih.gov/pubmed/?term=Do%C4%9Fan%20K), [Keskin L](https://www.ncbi.nlm.nih.gov/pubmed/?term=Keskin%20L), [Mert M](https://www.ncbi.nlm.nih.gov/pubmed/?term=Mert%20M), [Adaş M](https://www.ncbi.nlm.nih.gov/pubmed/?term=Ada%C5%9F%20M), [Tonguç M](https://www.ncbi.nlm.nih.gov/pubmed/?term=Tongu%C3%A7%20M), [Eroğlu M](https://www.ncbi.nlm.nih.gov/pubmed/?term=Ero%C4%9Flu%20M), [Kulaksızoğlu M](https://www.ncbi.nlm.nih.gov/pubmed/?term=Kulaks%C4%B1zo%C4%9Flu%20M), [Özcan M](https://www.ncbi.nlm.nih.gov/pubmed/?term=%C3%96zcan%20M), [Çınar N](https://www.ncbi.nlm.nih.gov/pubmed/?term=%C3%87%C4%B1nar%20N), [Kutbay NÖ](https://www.ncbi.nlm.nih.gov/pubmed/?term=Kutbay%20N%C3%96), [Dikbaş O](https://www.ncbi.nlm.nih.gov/pubmed/?term=Dikba%C5%9F%20O), [Bakıner O](https://www.ncbi.nlm.nih.gov/pubmed/?term=Bak%C4%B1ner%20O), [Turhan ÖT](https://www.ncbi.nlm.nih.gov/pubmed/?term=Turhan%20%C3%96T), [Tütüncüoğlu P](https://www.ncbi.nlm.nih.gov/pubmed/?term=T%C3%BCt%C3%BCnc%C3%BCo%C4%9Flu%20P), [Sarı R](https://www.ncbi.nlm.nih.gov/pubmed/?term=Sar%C4%B1%20R), [Melekoğlu R](https://www.ncbi.nlm.nih.gov/pubmed/?term=Meleko%C4%9Flu%20R), [Ayaz R](https://www.ncbi.nlm.nih.gov/pubmed/?term=Ayaz%20R), [Emral R](https://www.ncbi.nlm.nih.gov/pubmed/?term=Emral%20R), [Mumusoglu S](https://www.ncbi.nlm.nih.gov/pubmed/?term=Mumusoglu%20S), [Görar S](https://www.ncbi.nlm.nih.gov/pubmed/?term=G%C3%B6rar%20S), [Keşkek ŞÖ](https://www.ncbi.nlm.nih.gov/pubmed/?term=Ke%C5%9Fkek%20%C5%9E%C3%96), [Tosun ŞA](https://www.ncbi.nlm.nih.gov/pubmed/?term=Tosun%20%C5%9EA), [Çetinkaya ŞE](https://www.ncbi.nlm.nih.gov/pubmed/?term=%C3%87etinkaya%20%C5%9EE), [Temizkan Ş](https://www.ncbi.nlm.nih.gov/pubmed/?term=Temizkan%20%C5%9E), [Ünsal Ş](https://www.ncbi.nlm.nih.gov/pubmed/?term=%C3%9Cnsal%20%C5%9E), [Demir T](https://www.ncbi.nlm.nih.gov/pubmed/?term=Demir%20T), [Yüce T](https://www.ncbi.nlm.nih.gov/pubmed/?term=Y%C3%BCce%20T), [Aksoy Ü](https://www.ncbi.nlm.nih.gov/pubmed/?term=Aksoy%20%C3%9C), [Çınkır Ü](https://www.ncbi.nlm.nih.gov/pubmed/?term=%C3%87%C4%B1nk%C4%B1r%20%C3%9C), [Şimşek Y](https://www.ncbi.nlm.nih.gov/pubmed/?term=%C5%9Eim%C5%9Fek%20Y), [Uyar Y](https://www.ncbi.nlm.nih.gov/pubmed/?term=Uyar%20Y), [Türk Y](https://www.ncbi.nlm.nih.gov/pubmed/?term=T%C3%BCrk%20Y), [Pekkolay Z](https://www.ncbi.nlm.nih.gov/pubmed/?term=Pekkolay%20Z), [Hekimsoy Z](https://www.ncbi.nlm.nih.gov/pubmed/?term=Hekimsoy%20Z), [Cantürk Z](https://www.ncbi.nlm.nih.gov/pubmed/?term=Cant%C3%BCrk%20Z), [Üç ZA](https://www.ncbi.nlm.nih.gov/pubmed/?term=%C3%9C%C3%A7%20ZA).

1. [Sonmez A](https://www.ncbi.nlm.nih.gov/pubmed/?term=Sonmez%20A%5BAuthor%5D&cauthor=true&cauthor_uid=30244051), [Haymana C](https://www.ncbi.nlm.nih.gov/pubmed/?term=Haymana%20C%5BAuthor%5D&cauthor=true&cauthor_uid=30244051), [Bayram F](https://www.ncbi.nlm.nih.gov/pubmed/?term=Bayram%20F%5BAuthor%5D&cauthor=true&cauthor_uid=30244051), [Salman S](https://www.ncbi.nlm.nih.gov/pubmed/?term=Salman%20S%5BAuthor%5D&cauthor=true&cauthor_uid=30244051), [Dizdar OS](https://www.ncbi.nlm.nih.gov/pubmed/?term=Dizdar%20OS%5BAuthor%5D&cauthor=true&cauthor_uid=30244051), [Gurkan E](https://www.ncbi.nlm.nih.gov/pubmed/?term=Gurkan%20E%5BAuthor%5D&cauthor=true&cauthor_uid=30244051), [Kargili Carlıoglu A](https://www.ncbi.nlm.nih.gov/pubmed/?term=Kargili%20Carl%C4%B1oglu%20A%5BAuthor%5D&cauthor=true&cauthor_uid=30244051), [Barcin C](https://www.ncbi.nlm.nih.gov/pubmed/?term=Barcin%20C%5BAuthor%5D&cauthor=true&cauthor_uid=30244051), [Sabuncu T](https://www.ncbi.nlm.nih.gov/pubmed/?term=Sabuncu%20T%5BAuthor%5D&cauthor=true&cauthor_uid=30244051), [Satman I](https://www.ncbi.nlm.nih.gov/pubmed/?term=Satman%20I%5BAuthor%5D&cauthor=true&cauthor_uid=30244051); [**TEMD Study Group**](https://www.ncbi.nlm.nih.gov/pubmed/?term=TEMD%20Study%20Group%5BCorporate%20Author%5D)**. Turkish nationwide survEy of glycemic and other Metabolic parameters of patients with Diabetes mellitus (TEMD study).** [Diabetes Res Clin Pract.](https://www.ncbi.nlm.nih.gov/pubmed/30244051) 2018 Sep 20;146:138-147. doi: 10.1016/j.diabres.2018.09.010.

TEMD STUDY GROUP: [Guldiken S](https://www.ncbi.nlm.nih.gov/pubmed/?term=Guldiken%20S)11, [Ayturk S](https://www.ncbi.nlm.nih.gov/pubmed/?term=Ayturk%20S)11, [Yilmaz M](https://www.ncbi.nlm.nih.gov/pubmed/?term=Yilmaz%20M)12, [Asik M](https://www.ncbi.nlm.nih.gov/pubmed/?term=Asik%20M)13, [Dinccag N](https://www.ncbi.nlm.nih.gov/pubmed/?term=Dinccag%20N)14, [Cakmak R](https://www.ncbi.nlm.nih.gov/pubmed/?term=Cakmak%20R)14, [Turker F](https://www.ncbi.nlm.nih.gov/pubmed/?term=Turker%20F)14, [Idiz C](https://www.ncbi.nlm.nih.gov/pubmed/?term=Idiz%20C)14, [Hacisahinogullari H](https://www.ncbi.nlm.nih.gov/pubmed/?term=Hacisahinogullari%20H)14, [Bagdemir E](https://www.ncbi.nlm.nih.gov/pubmed/?term=Bagdemir%20E)14, [Yildiz B](https://www.ncbi.nlm.nih.gov/pubmed/?term=Yildiz%20B)14, [Yumuk VD](https://www.ncbi.nlm.nih.gov/pubmed/?term=Yumuk%20VD)15, [Haliloglu O](https://www.ncbi.nlm.nih.gov/pubmed/?term=Haliloglu%20O)15, [Sancak S](https://www.ncbi.nlm.nih.gov/pubmed/?term=Sancak%20S)16, [Ozsari L](https://www.ncbi.nlm.nih.gov/pubmed/?term=Ozsari%20L)17, [Cagiltay E](https://www.ncbi.nlm.nih.gov/pubmed/?term=Cagiltay%20E)17, [Deyneli O](https://www.ncbi.nlm.nih.gov/pubmed/?term=Deyneli%20O)18, [Imre E](https://www.ncbi.nlm.nih.gov/pubmed/?term=Imre%20E)18, [Gonen S](https://www.ncbi.nlm.nih.gov/pubmed/?term=Gonen%20S)19, [Boysan SN](https://www.ncbi.nlm.nih.gov/pubmed/?term=Boysan%20SN)19, [Altuntas Y](https://www.ncbi.nlm.nih.gov/pubmed/?term=Altuntas%20Y)20, [Ozturk FY](https://www.ncbi.nlm.nih.gov/pubmed/?term=Ozturk%20FY)20, [Mert M](https://www.ncbi.nlm.nih.gov/pubmed/?term=Mert%20M)21, [Piskinpasa H](https://www.ncbi.nlm.nih.gov/pubmed/?term=Piskinpasa%20H)21, [Aydin H](https://www.ncbi.nlm.nih.gov/pubmed/?term=Aydin%20H)22, [Imamoglu S](https://www.ncbi.nlm.nih.gov/pubmed/?term=Imamoglu%20S)23, [Ersoy C](https://www.ncbi.nlm.nih.gov/pubmed/?term=Ersoy%20C)24, [Gul OO](https://www.ncbi.nlm.nih.gov/pubmed/?term=Gul%20OO)24, [Kucuksarac Kiyici S](https://www.ncbi.nlm.nih.gov/pubmed/?term=Kucuksarac%20Kiyici%20S)25, [Cetinarslan B](https://www.ncbi.nlm.nih.gov/pubmed/?term=Cetinarslan%20B)26, [Selek A](https://www.ncbi.nlm.nih.gov/pubmed/?term=Selek%20A)26, [Dogru T](https://www.ncbi.nlm.nih.gov/pubmed/?term=Dogru%20T)27, [Kirik A](https://www.ncbi.nlm.nih.gov/pubmed/?term=Kirik%20A)27, [Kebapci N](https://www.ncbi.nlm.nih.gov/pubmed/?term=Kebapci%20N)28, [Efe B](https://www.ncbi.nlm.nih.gov/pubmed/?term=Efe%20B)28, [Kaya A](https://www.ncbi.nlm.nih.gov/pubmed/?term=Kaya%20A)29, [Cordan I](https://www.ncbi.nlm.nih.gov/pubmed/?term=Cordan%20I)29, [Baldane S](https://www.ncbi.nlm.nih.gov/pubmed/?term=Baldane%20S)30, [Kirac CO](https://www.ncbi.nlm.nih.gov/pubmed/?term=Kirac%20CO)30, [Demirci I](https://www.ncbi.nlm.nih.gov/pubmed/?term=Demirci%20I)31, [Capa Z](https://www.ncbi.nlm.nih.gov/pubmed/?term=Capa%20Z)31, [Cesur M](https://www.ncbi.nlm.nih.gov/pubmed/?term=Cesur%20M)32, [Yetkin I](https://www.ncbi.nlm.nih.gov/pubmed/?term=Yetkin%20I)33, [Corapcioglu D](https://www.ncbi.nlm.nih.gov/pubmed/?term=Corapcioglu%20D)34, [Canlar S](https://www.ncbi.nlm.nih.gov/pubmed/?term=Canlar%20S)34, [Bulent Yildiz O](https://www.ncbi.nlm.nih.gov/pubmed/?term=Bulent%20Yildiz%20O)35, [Sendur SN](https://www.ncbi.nlm.nih.gov/pubmed/?term=Sendur%20SN)35, [Cakir B](https://www.ncbi.nlm.nih.gov/pubmed/?term=Cakir%20B)36, [Ozdemir D](https://www.ncbi.nlm.nih.gov/pubmed/?term=Ozdemir%20D)36, [Corakci A](https://www.ncbi.nlm.nih.gov/pubmed/?term=Corakci%20A)37, [Kutlu M](https://www.ncbi.nlm.nih.gov/pubmed/?term=Kutlu%20M)38, [Bascil Tutuncu N](https://www.ncbi.nlm.nih.gov/pubmed/?term=Bascil%20Tutuncu%20N), [Bozkus Y](https://www.ncbi.nlm.nih.gov/pubmed/?term=Bozkus%20Y)39, [Cakal E](https://www.ncbi.nlm.nih.gov/pubmed/?term=Cakal%20E)40, [Demirbas B](https://www.ncbi.nlm.nih.gov/pubmed/?term=Demirbas%20B)41, [Ertek S](https://www.ncbi.nlm.nih.gov/pubmed/?term=Ertek%20S)42, [Altay M](https://www.ncbi.nlm.nih.gov/pubmed/?term=Altay%20M)43, [Dagdeviren M](https://www.ncbi.nlm.nih.gov/pubmed/?term=Dagdeviren%20M)43, [Abedi AH](https://www.ncbi.nlm.nih.gov/pubmed/?term=Abedi%20AH)44, [Cetinkalp S](https://www.ncbi.nlm.nih.gov/pubmed/?term=Cetinkalp%20S)45, [Ozisik H](https://www.ncbi.nlm.nih.gov/pubmed/?term=Ozisik%20H)45, [Oruk GG](https://www.ncbi.nlm.nih.gov/pubmed/?term=Oruk%20GG)46, [Yener S](https://www.ncbi.nlm.nih.gov/pubmed/?term=Yener%20S)47, [Saydam BO](https://www.ncbi.nlm.nih.gov/pubmed/?term=Saydam%20BO)47, [Guney E](https://www.ncbi.nlm.nih.gov/pubmed/?term=Guney%20E)48, [Unubol M](https://www.ncbi.nlm.nih.gov/pubmed/?term=Unubol%20M)48, [**Yaylali GF**](https://www.ncbi.nlm.nih.gov/pubmed/?term=Yaylali%20GF)**49**, [Topsakal S](https://www.ncbi.nlm.nih.gov/pubmed/?term=Topsakal%20S)49, [Hekimsoy Z](https://www.ncbi.nlm.nih.gov/pubmed/?term=Hekimsoy%20Z)50, [Akbaba G](https://www.ncbi.nlm.nih.gov/pubmed/?term=Akbaba%20G)51, [Aslan I](https://www.ncbi.nlm.nih.gov/pubmed/?term=Aslan%20I)52, [Balci MK](https://www.ncbi.nlm.nih.gov/pubmed/?term=Balci%20MK)53, [Dalkiran S](https://www.ncbi.nlm.nih.gov/pubmed/?term=Dalkiran%20S)53, [Akbay E](https://www.ncbi.nlm.nih.gov/pubmed/?term=Akbay%20E)54, [Gul K](https://www.ncbi.nlm.nih.gov/pubmed/?term=Gul%20K)55, [Agbaht K](https://www.ncbi.nlm.nih.gov/pubmed/?term=Agbaht%20K)56, [Yilmaz MO](https://www.ncbi.nlm.nih.gov/pubmed/?term=Yilmaz%20MO)57, [Bozkirli E](https://www.ncbi.nlm.nih.gov/pubmed/?term=Bozkirli%20E)58, [Tetiker BT](https://www.ncbi.nlm.nih.gov/pubmed/?term=Tetiker%20BT)59, [Cetinkaya Altuntas S](https://www.ncbi.nlm.nih.gov/pubmed/?term=Cetinkaya%20Altuntas%20S)59, [Atmaca A](https://www.ncbi.nlm.nih.gov/pubmed/?term=Atmaca%20A)60, [Durmuş ET](https://www.ncbi.nlm.nih.gov/pubmed/?term=Durmu%C5%9F%20ET)60, [Mete T](https://www.ncbi.nlm.nih.gov/pubmed/?term=Mete%20T)61, [Kutluturk F](https://www.ncbi.nlm.nih.gov/pubmed/?term=Kutluturk%20F)62, [Kucukler FK](https://www.ncbi.nlm.nih.gov/pubmed/?term=Kucukler%20FK)63, [Dikbas O](https://www.ncbi.nlm.nih.gov/pubmed/?term=Dikbas%20O)64, [Akin S](https://www.ncbi.nlm.nih.gov/pubmed/?term=Akin%20S)65, [Nuhoglu I](https://www.ncbi.nlm.nih.gov/pubmed/?term=Nuhoglu%20I)66, [Ersoz HO](https://www.ncbi.nlm.nih.gov/pubmed/?term=Ersoz%20HO)66, [Bayraktaroglu T](https://www.ncbi.nlm.nih.gov/pubmed/?term=Bayraktaroglu%20T)67, [Sisman P](https://www.ncbi.nlm.nih.gov/pubmed/?term=Sisman%20P)68, [Sahin I](https://www.ncbi.nlm.nih.gov/pubmed/?term=Sahin%20I)69, [Cetin S](https://www.ncbi.nlm.nih.gov/pubmed/?term=Cetin%20S)69, [Capoglu I](https://www.ncbi.nlm.nih.gov/pubmed/?term=Capoglu%20I)70, [Akbas EM](https://www.ncbi.nlm.nih.gov/pubmed/?term=Akbas%20EM)70, [Ucler R](https://www.ncbi.nlm.nih.gov/pubmed/?term=Ucler%20R)71, [Eren MA](https://www.ncbi.nlm.nih.gov/pubmed/?term=Eren%20MA)72, [Tuzcu AK](https://www.ncbi.nlm.nih.gov/pubmed/?term=Tuzcu%20AK)73, [Pekkolay Z](https://www.ncbi.nlm.nih.gov/pubmed/?term=Pekkolay%20Z)73, [Ozkaya M](https://www.ncbi.nlm.nih.gov/pubmed/?term=Ozkaya%20M)74, [Araz M](https://www.ncbi.nlm.nih.gov/pubmed/?term=Araz%20M)75.

1. [Yaylalı YT](https://www.ncbi.nlm.nih.gov/pubmed/?term=Yaylal%C4%B1%20YT%5BAuthor%5D&cauthor=true&cauthor_uid=30516522), [**Fidan-Yaylalı G**](https://www.ncbi.nlm.nih.gov/pubmed/?term=Fidan-Yaylal%C4%B1%20G%5BAuthor%5D&cauthor=true&cauthor_uid=30516522), [Can B](https://www.ncbi.nlm.nih.gov/pubmed/?term=Can%20B%5BAuthor%5D&cauthor=true&cauthor_uid=30516522), [Şenol H](https://www.ncbi.nlm.nih.gov/pubmed/?term=%C5%9Eenol%20H%5BAuthor%5D&cauthor=true&cauthor_uid=30516522), [Kılınç M](https://www.ncbi.nlm.nih.gov/pubmed/?term=K%C4%B1l%C4%B1n%C3%A7%20M%5BAuthor%5D&cauthor=true&cauthor_uid=30516522), [Yurtdaş M](https://www.ncbi.nlm.nih.gov/pubmed/?term=Yurtda%C5%9F%20M%5BAuthor%5D&cauthor=true&cauthor_uid=30516522). **Predictive power of different obesity measures for the presence of diastolic dysfunction.** [Turk Kardiyol Dern Ars.](https://www.ncbi.nlm.nih.gov/pubmed/?term=Predictive+power+of+different+obesity+measures+for+the+presence+of+diastolic+dysfunction) 2018 Dec;46(8):651-658.
2. Akinci G, Topaloglu H, Demir T, Danyeli AE, Talim B, Keskin FE, Kadioglu P, Talip E, Altay C, **Yaylali GF**, Bilen H, Nur B, Demir L, Onay H, Akinci B. [**Clinical spectra of neuromuscular manifestations in patients with lipodystrophy: A multicenter study.**](https://www.ncbi.nlm.nih.gov/pubmed/28754454) Neuromuscul Disord. 2017 Oct;27(10):923-930. doi: 10.1016/j.nmd.2017.05.015. Epub 2017 Jun
3. Akinci B, Onay H, Demir T, Savas-Erdeve Ş, Gen R, Simsir IY, Keskin FE, Erturk MS, Uzum AK, **Yaylali GF**, Ozdemir NK, Atik T, Ozen S, Yurekli BS, Apaydin T, Altay C, Akinci G, Demir L, Comlekci A, Secil M, Oral EA. [**Clinical presentations, metabolic abnormalities and end-organ complications in patients with familial partial lipodystrophy.**](https://www.ncbi.nlm.nih.gov/pubmed/28641778) Metabolism. 2017 Jul;72:109-119.
4. Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, Lingvay I, Rosenstock J, Seufert J, Warren ML, Woo V, Hansen O, Holst AG, Pettersson J, Vilsbøll T; **SUSTAIN-6 Investigators**. [**Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.**](https://www.ncbi.nlm.nih.gov/pubmed/27633186) N Engl J Med. 2016 Nov 10;375(19):1834-1844.
5. Topsakal S, Akin F, Turgut S, Yerlikaya E, **Yaylali GF** **Serum leptin levels and GHR-d3/fl gene polymorphism in acromegalic patients with thyroid nodules.** Adv Clin Exp Med 2017;26(2):281–286
6. Gurbulak S**,** Akin F, Yerlikaya E, **Yaylali GF**, Topsakal S, Tanrverdi H, Akdag B**,** Kaptanoglu B **Adiponectin and Cardiac Hypertrophy in Acromegaly.** Adv Clin Exp Med 2016, 25, 3, 449–455
7. **Fidan-Yaylali G,** Yaylali YT, Erdogan Ç, Can B, Senol H, Gedik-Topçu B, Topsakal S.[**The Association between Central Adiposity and Autonomic Dysfunction in Obesity.**](http://www.ncbi.nlm.nih.gov/pubmed/27194294)Med Princ Pract. 2016 May 19. [Epub ahead of print]
8. **Fidan Yaylali G,** Yaylali O, Yuksel D, Topsakal S, Kabay B, Dursunoglu N **Tuberculosis with adrenal insufficiency mimicking malignancy in FDG-PET images.** Nobel Med 2016; 12(3): 73-36
9. **Fidan-Yaylalı G**, Dodurga Y, Seçme M, Elmas L.[**Antidiabetic exendin-4 activates apoptotic pathway and inhibits growth of breast cancer cells.**](http://www.ncbi.nlm.nih.gov/pubmed/26399993) Tumour Biol. 2016 Feb;37(2):2647-53. doi: 10.1007/s13277-015-4104-9
10. **Fidan Yaylali G**, Turgut S, Akin F, Ozkan S, Tural M, Tunc Ata M,Ozlu C, Isler K. **Visfatin Levels in Subclinical Hypothyroidism** Int J Pept Res Ther 2016 22: 11-14
11. [Topsakal S, Akin F, Turgut S, **Yaylali GF,** Herek D, Ayada C **Relationship of apelin, procalcitonin, and fetuin-A levels with carotid intima-media thickness in acromegalic patients**.](http://www.ncbi.nlm.nih.gov/pubmed/25398764) Ann Clin Biochem. [Ann Clin Biochem.](http://www.ncbi.nlm.nih.gov/pubmed/?term=Topsakal+S%2C+Akin+F%2C+Turgut+S%2C+Yaylali+GF%2C+Herek+D%2C+Ayada+C++Relationship+of+apelin%2C+procalcitonin%2C+and+fetuin-A+levels+with+carotid+intima-media+thickness+in+acromegalic+patients.) 2015 Jul;52(Pt 4):456-61
12. Yorukoglu A, Yalcin N, Avci A, Cakalagaoglu F, **Yaylali G**, Akin F, Haciyanli M, Ozden A. [**Significance of IMP3, Nucleophosmin, and Ki-67 Expression in Papillary Thyroid Carcinoma.**](http://www.ncbi.nlm.nih.gov/pubmed/25389240) Int J Surg Pathol. 2015 Feb;23(1):5-12
13. **Yaylali GF**, Bichet DG, Okur V, Levin K. Semerci NC. Analysis of a Novel *AVPR2* **Mutation in a Turkish Family with Nephrogenic Diabetes Insipidus** Int J Hum Genet,2013 13(3): 171-175
14. Topsakal S, Erurker T, Akin F, **Yaylali GF**, Yerlikaya E, Kaptanoglu B. **Heel pain and Comorbid Conditions in Obese patients.** Journal of Musculosceletal Pain. 2014 March ;22(1) 38-42.
15. Gurbulak S, **Yaylali GF**, Yerlikaya E, Akin F, Topsakal S, Tanrverdi H, Akdag B, Aslan AR. [**Resistin and leptin levels in acromegaly: lack of correlation with echocardiographic findings.**](http://www.ncbi.nlm.nih.gov/pubmed/23360845) J Investig Med. 2013 Mar;61(3):582-5.
16. Yaylali YT, **Yaylali GF**, Susam I, Akin F, Turgut S. [**Insulin-like growth factor-I gene polymorphisms and left ventricular function in Turkish obese women with insulin resistance.**](http://www.ncbi.nlm.nih.gov/pubmed/22057613)Saudi Med J. 2011 Nov;32(11):1199-201.

# Karabulut A, Yaylali GF, Demirlenk S, Sevket O, Acun A. Evaluation of body fat distribution in PCOS and its association with carotid atherosclerosis and insulin resistance. Gynecol Endocrinol. 2012 Feb;28(2):111-4. doi: 10.3109/09513590.2011.589929. [Epub ahead of print]

# Yaylali YT, Yaylali GF, Akin F, Susam I, Bastemir M. [Effects of Substitutive Therapy on Right Ventricular Systolic and Diastolic Functions in Patients with Idiopathic Hypogonadotropic Hypogonadism.](http://www.ncbi.nlm.nih.gov/pubmed/20820132) J Endocrinol Invest. 2011 Apr;34(4):e97-101. Epub 2010 Sep 2.

#  Yaylali GF, Tekekoglu S, Akin F [Sexual dysfunction in obese and overweight women.](http://www.ncbi.nlm.nih.gov/pubmed/20485360) Int J Impot Res. 2010 Jul;22(4):220-6. Epub 2010 May 20.

#  Fidan Yaylali G, Akin F, Turgut S, Kursunluoglu R .[IGF-1 gene polymorphism in obese patients with insulin resistance.](http://www.ncbi.nlm.nih.gov/pubmed/19680783?itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum&ordinalpos=4) Mol Biol Rep. 2010 Jan;37(1):529-33.

# Akin F, Yaylali GF, Turgut S, Kaptanoglu B. [Growth hormone/insulin-like growth factor axis in patients with subclinical thyroid dysfunction.](http://www.ncbi.nlm.nih.gov/pubmed/19111490?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum) Growth Horm IGF Res. 2009 Jun;19(3):252-5. Epub 2008 Dec 25.

# Yaylali GF, Akin F, Bastemir M, Yaylali YT, Ozden A. Phaeochromocytoma combined with subclinical Cushing's syndrome and pituitary microadenoma.Clin Invest Med. 2008;31(3):E176-81.

# Akin F, Yaylali GF, Bastemir M. The use of lithium carbonate in the preparation for definitive therapy in hyperthyroid patients.Med Princ Pract. 2008;17(2):167-70. Epub 2008 Feb 19.

# Akin F, Yaylali GF, Bastemir M, Yapar B. Effect of Methimazole on Warfarin anticoagulation in a case of Graves’ Disease. Blood Coaguation Fibrinolysis 2008; 19(1):89-91

# Akin F, Bastemir M, Yaylali GF, Alkis E., Kaptanoglu B.Growth hormone/insulin like growth factor axis in patients with subclinical hypothyroidism. Clin Endocrinol (Oxf). 2008 Jun;68(6):1009-10

1. Bastemir M .,Akin F., **Yaylali GF. The PPAR-Gamma Activator Rosiglitazone Fails to Lower Plasma Growth Hormone and Insulin-Like Growth Factor-1 Levels in Patients with Acromegaly**. Neuroendocrinology 2007; 86(2): 119-123
2. Fenkci S, Rota S, Sabir N, **Fidan Yaylalı G,** Sermez Y **Effects of sibutramine on Insulin resistance, Metabolic Parameters and Abdominal Fat Mass**Turkiye Klinikleri J Med Sci 2007, 27:501-507
3. [Colakoglu M, **Yaylali GF**, Colakoglu NY, Yilmaz M.](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=16449014&ordinalpos=2&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum) **Successful treatment of visceral leishmaniasis with fluconazole and allopurinol in a patient with renal failure.**Scand J Infect Dis. 2006;38(2):152-4.
4. [Fenkci SM, **Fidan Yaylali G**, Sermez Y, Akdam H, Sabir N, Kirac S.](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=15947115&ordinalpos=2&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum) **Malign cystic glucagonoma presented with diabetic ketoacidosis: case report with an update**.Endocr Relat Cancer. 2005 Jun;12(2):449-54.
5. [Cobankara V, **Fidan G**, Turk T, Zencir M, Colakoglu M, Ozen S.](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=15515779&ordinalpos=3&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum) **The prevalence of familial Mediterranean fever in the Turkish province of Denizli: a field study with a zero patient design**.Clin Exp Rheumatol. 2004 Jul-Aug;22(4 Suppl 34):S27-30.

**ORAL and POSTER PRESENTATIONS**

1. Islam Cagrı Bosna , Nese Cinar , Tuba Edgunlu , Gulhan Akbaba , Guzin Yaylali , Sevim Karakas Celik , Ebru Onalan Ete , Aycan Celik & Murside Gizem Bircan The clinical effects of miR-26a, miR-16, let-7,miR-128a and miR-223 in acromegaly patients 23 rd European Congress of Endocrinology 22-26 May 2021 Endocrine Abstracts (2021) **73** OC8.5 | DOI: [10.1530/endoabs.73.OC8.5](https://doi.org/10.1530/endoabs.73.OC8.5)
2. Halil Güner, Guzin Yaylali, Mücahit Seçme , İbrahim Açıkbaş & Hande Şenol

 Investigation of 5 alpha reductase-1 and aromatase enzyme levels, gene expressions and kisspeptin and nesfatin-1 levels in male patients with metabolic syndrome and hypogonadism 23 rd European Congress of Endocrinology 22-26 May 2021 Endocrine Abstracts (2021) **73** AEP192 | DOI: [10.1530/endoabs.73.AEP192](https://doi.org/10.1530/endoabs.73.AEP192)

1. SM Fenkci, S Topsakal, **GF Yaylalı**, N Yalcın. **Ectopic TSH secreting adenoma result from nasopharynx.** 18 th International Congress of Endocrinology 1-4 December 2018 Cape Town, South Africa
2. **GF Yaylalı**, S Taban, S Topsakal, SM Fenkci. **Chordoma as a rare cause of pituitary insufficiency: A case report** 18 th International Congress of Endocrinology 1-4 December 2018 Cape Town, South Africa
3. B Yapar, SM Fenkci, **GF Yaylalı**, Y Enli, O Oztekin, S Topsakal**. Effect of metformin in combination with cyproterpne acetate+ ethinyl estrodiol treatment on antioxidant status in polycystic ovary syndrome** .18 th International Congress of Endocrinology 1-4 December 2018 Cape Town, South Africa
4. S Topsakal, F Altıntaş, **GF Yaylalı**, SM Fenkci, S Calışkan. **Epiregulin levels in patients with polycystic ovary syndrome** 18 th International Congress of Endocrinology 1-4 December 2018 Cape Town, South Africa
5. F. Bayram, A. Sonmez, C. Haymana, T. Sabuncu, O.S. Dizdar, E. Gurkan, A. Kargili Carlioglu, K. Agbaht, D. Sen, B. Kucuk Bicer, C. Barcin, S. Salman, T. Tetiker, M.K. Balci, N. Kebapci, C. Ersoy, V. Yumuk, I. Satman, **Temd study group** (Turkey) **Blood lipids, diabetic complications and the physician attitudes on dyslipidemia treatment; data from the Turkish nationwide survey of glycemic and other metabolic parameters of patients with diabetes.** 86th EAS Congress, May 05-08, 2018 Lisbon , Portugal
6. Sönmez A, Yumuk V,Haymana C, et al **Temd study group** (Turkey) **Impact of obesity on the metabolic control of Type 2 Diabetes: results of Turkish Nationwide Survey of glycemic and other metabolic parameters of patients with diabetes mellitus (TEMD study**),25th European Congress on Obesity,23-26 May Vienna ,Austria
7. A. Sonmez, C. Haymana , F. Bayram , S. Salman , O. Dizdar , E. Gurkan , A. Kargılı Carlıoglu , B. Kucuk Bicer , C. Barcin , T. Sabuncu , I. Satman , T**. Temd Study Group .** Turkish nationwide survey of glycemic and other metabolic parameters of patients with diabetes melitus (TEMD Study) IDF Congress. 4-8 December 2017 Abu Dhabi.
8. YT. Yaylali**, G. Fidan-Yaylali**, O. Dedeoglu, H. Senol. **The association between osteocalcin and epicardial fat tissue in obesity.** European Heart Congress 26-30 August 2017 Barcelona ; Journal ( 2017 ) 38 ( Supplement ), 916.
9. **Fidan-Yaylalı G**, Dodurga Y, Seçme M, Elmas L.[**Antidiabetic exendin-4 activates apoptotic pathway and inhibits growth of breast cancer cells.**](http://www.ncbi.nlm.nih.gov/pubmed/26399993)ESHG , 2017
10. Topsakal S, **Fidan Yaylalı G,** Fenkci SM **Can night eating syndrome increase basal metabolic rate?** 19th European Congress of Endocrinology 20-23 May 2017, Lisbon, Portugal
11. Fenkci SM **,** Coskun M**,** Topsakal S , **Fidan Yaylalı G, Our experience of strain elastography in the evaluation of thyroid nodules.** 19th European Congress of Endocrinology 20-23 May 2017, Lisbon, Portugal
12. Fenkci SM **,** Topsakal S , **Fidan Yaylalı G** **ACTH deficiency in patient with bilateral adrenal adenomas.**  19th European Congress of Endocrinology 20-23 May 2017, Lisbon, Portugal.
13. **Fidan Yaylalı G,** Topsakal S, Degirmencioglu, Fenkci SM**. Pituitary metastases of lung cancer presenting with hypopituatrism**. 19th European Congress of Endocrinology 20-23 May 2017, Lisbon, Portugal.
14. Dedeoglu O, **Fidan Yaylalı G**, Herek D, Topsakal S, Akin F, Senol H. **Association of body fat distribution and carotid intima media thicknesss with Vitamin D in obese premenopausal women** .18th European Congress of Endocrinology 28-31 May 2016, Munich, Germany
15. Dedeoglu O, **Fidan Yaylalı G**, Akin F, Topsakal S,Demir S , Senol H. **Is Pentraxin 3 a marker in pathogenesis of central obesity?** 18th European Congress of Endocrinology 28-31 May 2016, Munich, Germany
16. Dedeoglu O, **Fidan Yaylalı G,** Yaylalı T, Topsakal S, Akin F, Herek D, Senol H **Effect of osteocalcin on fat distrubution in premenopausal obese women.** 18th European Congress of Endocrinology 28-31 May 2016, Munich, Germany
17. Akin F,Erol V, Erturk S, Kiroglu Y, Topsakal S, **Fidan Yaylalı G Acute myeloid leukemia presenting with panhypopituitarism and diabetes insipidus.** 18th European Congress of Endocrinology 28-31 May 2016, Munich, Germany
18. Güleryüz B, Akin F, Topsakal S, **Fidan Yaylali G** Turgut S , Tunc- Ata M, Mergen Dalyanoğlu M **Relationship to TSH, and interleukin levels patients with Hashimoto’s Thyroiditis**. 18th European Congress of Endocrinology 28-31 May 2016, Munich, Germany
19. **Fidan Yaylali G**, Dundar Ok Z, Erturk MS,Akin F, Topsakal S . **Atypical subacute thyroiditis** 17th European Congress of Endocrinology 16-20 May 2015, Dublin, Ireland
20. **Fidan Yaylali G** ,Güleryüz B, Akin F, Turgut S , Topsakal S Tunc- Ata M, Mergen Dalyanoğlu M. **IL-2, IL-4, IL-5, IFN-γ and TNF-α levels in Turkish patients with Hashimoto's thyroiditis.** 17th European Congress of Endocrinology 16-20 May 2015, Dublin, Ireland
21. **Fidan Yaylali G** , Gokoz Dogu G, Demiray AG, Ergin A, Yaren A, Akin F. **Effects of megestrol acetate on adrenal function and survival in cancer patients.**17th European Congress of Endocrinology 16-20 May 2015, Dublin, Ireland
22. Topsakal S, Güleryüz B, Tunc- Ata M, Akin F, **Fidan Yaylali G**, Mergen Dalyanoğlu M , Turgut S. **Relation of vitamin D receptor gene polymorphism FOK-I in subtype of Hashimoto's thyroiditis.** 17th European Congress of Endocrinology 16-20 May 2015, Dublin, Ireland
23. Akin F, Güleryüz B, , Turgut S , Topsakal S, **Fidan Yaylali G** ,Tunc- Ata M, Mergen Dalyanoğlu M. **Is vitamin D receptor gene polymorphism TaqI effect the occurrence and subtype of Hashimoto's thyroiditis?** 17th European Congress of Endocrinology 16-20 May 2015, Dublin, Ireland
24. Tural M, Akin F, Turgut S, **Yaylali GF**, Ata MT, Ozkan S & Erturk MS. **IGF1 gene polymorphism in Polycystic Ovary Syndrome** 16th European Congress of Endocrinology 3-7May 2014, Wroclaw, Poland. O.C.9.5 , 2014
25. Akin F, Erturk MS, **Yaylali GF** & Soysal E. **Primary hyperparathyroidism with severe hypercalcemia during pregnancy** 16th European Congress of Endocrinology 3-7May 2014, Wroclaw, Poland. P264 , 2014
26. **Yaylali GF**, Erturk MS, Akin F, Yalcın N, Gurkan H, Ozden A & Guldiken S. **Coexisting hurthle cell neoplasm and thyroid hormone resistance**.16th European Congress of Endocrinology 3-7May 2014, Wroclaw, Poland. P263 , 2014
27. Topsakal S, Akin F**, Yaylali GF,** **Anthropometric and biochemical parameters in older women with a history of gestational diabetes** 16th European Congress of Endocrinology 3-7May 2014, Wroclaw, Poland. P380 , 2014
28. Topsakal S, Akin F, **Yaylali GF**. **Increased prolactin levels cause increased MPV in women with PCOS** 16th European Congress of Endocrinology 3-7May 2014, Wroclaw, Poland. P1027 , 2014
29. Akin F, Karadag F, Berker M, **Yaylali GF**. **From Depression to Cushing Syndrome: An Atypical Presentation of a Cushing Disease**. 16th Congress of the European Neuroendocrine Association 10-13 September ENEA 2014 Sofia, Bulgaria.
30. Akin F**, Yaylali GF**, Yilmaz H, Erturk MS**. A Case of Prolactinoma Resistant to Dopamin Agonists.** 16th Congress of the European Neuroendocrine Association 10-13 September ENEA 2014 Sofia, Bulgaria
31. **Yaylali Guzin Fidan;** Akin Fulya; Yerlikaya Emrah; Topsakal Senay; Herek Duygu,[**Cushing's disease recurrence after pregnancy**](http://www.endocrine-abstracts.org/ea/0032/ea0032P940.htm)  15 th European Congress of Endocrinology (ECE 2013), 27 April- 1 May 2013 Copenhagen, Denmark
32. Topsakal Senay; Akin Fulya; **Yaylali Guzin**; Turgut Sebahat; Herek Duygu; Yerlikaya Emrah; Ayada Ceylan, [**Fetuin-A can be used as a marker of acromegaly**](http://www.endocrine-abstracts.org/ea/0032/ea0032P935.htm) ,15 th European Congress of Endocrinology (ECE 2013), 27 April- 1 May 2013 Copenhagen, Denmark
33. Topsakal Senay; Akin Fulya; Turgut Sebahat; Herek Duygu; **Yaylali Guzin**; Yerlikaya Emrah; Ayada Ceylan ,**[Relation with carotid intima media thickness and procalcitonin in acromegalic patients](http://www.endocrine-abstracts.org/ea/0032/ea0032P946.htm)**15 th European Congress of Endocrinology (ECE 2013), 27 April- 1 May 2013 Copenhagen, Denmark
34. Topsakal Senay; Akin Fulya; **Yaylali Guzin**; Turgut Sebahat; Herek Duygu; Yerlikaya Emrah; Ayada Ceylan, [**Can apelin level used as a marker of active and inactive acromegaly?**](http://www.endocrine-abstracts.org/ea/0032/ea0032p962.htm) ,15 th European Congress of Endocrinology (ECE 2013), 527 April- 1 May 2013 Copenhagen, Denmark
35. Yerlikaya Emrah; Akin Fulya; Turgut Sebahat; **Yaylali Guzin**; Topsakal Senay; Ayada Ceylan; Hatipoglu Celile [**Plasma kisspeptin levels in polycystic ovary syndrome**](http://www.endocrine-abstracts.org/ea/0032/ea0032P618.htm) ,15 th European Congress of Endocrinology (ECE 2013), 27 April- 1 May 2013 Copenhagen, Denmark
36. Yerlikaya Emrah; Akin Fulya; Turgut Sebahat; **Yaylali Guzin**; Topsakal Senay; Ayada Ceylan; Hatipoglu Celile **Relation of plasma kisspeptin levels with obesity and insulin resistance in polycystic ovary syndrome,**15 th European Congress of Endocrinology (ECE 2013), 27 April- 1 May 2013 Copenhagen, Denmark
37. Yerlikaya E **,** Akin F, **Fidan Yaylali G**, Topsakal S. **Misdiagnosis of hypocortisolemia based on early morning cortisol: A case report** 12 th ESE postgraduate course in Clinical Endocrinology, 18-21 October 2012 , Antalya , Turkey (oral presentation)
38. Yerlikaya E **,** Akin F, **Fidan Yaylali G**, Topsakal S, **Complete remission of acromagaly with the long acting somatostatin analog as a fisrst line treatment: A case report** 12 th ESE postgraduate course in Clinical Endocrinology, 18-21 October 2012 , Antalya , Turkey (oral presentation)
39. Topsakal S, Erürker T,Akin F, **Yaylali G**, Yerlikaya E, Kaptanoglu B. **Plantar heel pain and relation with different diseases in obese Turkish patients.** 15th International &14 th European Congress of Endocrinology (ICE/ECE 2012), 5-9 May 2012, Florence, Italy.
40. Y.T. Yaylalı, **G.F. Yaylalı**, F. Akın, I. Susam, M. Başdemir “**Effects of Testosterone Therapy on Right Ventricular Systolic and Diastolic Function in Patients with Idiopathic Hypogonodotropic Hypogonadizm”** 6th Congress of Update in Cardiology and Cardiovascular Surgery In conjunction with 59 th International Congress of the European Society for Cardiovascular Surgery” International Journal of Cardiology Vol.140, Suppl. 1 044 ,(p13) April 16-18 2010, Izmir,Turkey.
41. Y.T. Yaylalı, **G.F. Yaylalı**, I. Susam, F. Akın, S. Turgut,”**IGF Gene Polymorhisims and Left Ventricular Function In Turkısh Obese Women with Insulin Resistance**” 6th Congress of Update in Cardiology and Cardiovascular Surgery In conjunction with 59 th International Congress of the European Society for Cardiovascular Surgery” International Journal of Cardiology Vol.140, Suppl. 1 051 ,(p15) April 16-18 2010, Izmir,Turkey
42. **Yaylali GF,** Akin F, Turgut S, Kursunluoglu R**. IGF-1 gene polymorphism in obese patıents with insulin resistance** 11th European Congess of Endocrinology, 25-29 April 2009, İstanbul , Turkey
43. **Yaylali GF,** Tekekoglu S, Akin F **Sexual dysfunction in women with obesity** 11th European Congess of Endocrinology, 25-29 April 2009, İstanbul , Turkey
44. Sermez Y, **Yaylalı GF,** Senturk BA, Satur N, Ustuner F, Roto S. **Simple waist circumference measurement highyl correlated with abdominal obesity and its related metabolic disorders** IFCC World Lab Fortaleza 28 September- 2 October 2008
45. Cobankara V , **Fidan G**,Liman S, Yalçın N, Pekdemirli E, Süzer T. , Cırak B, Colakoglu M, Kılıç İ. **Tuberculosis meningoencephalitis developed during treatment for systemic lupus erythematosus** Annual European Congress of Rheumatology EULAR 12-15 June 2002, Stockholm, Sweeden
46. Sermez Y, **Fidan G**, Oruç N, Karabulut N. **An ochronosis case associated with spinal changes similar to ankylosingspondylitis and hip osteopenia** IBMS ECTS 2001 1st Joint Meeting of the International and Mineral Societ and the European Calcified Tissue society June5- 10 2001, Madrıd, Spaın
47. Sermez Y , **Fidan G**, Oruç N, Sabir N, Erciyas F. **The changes of serum antithrombin III levels following weight loss in obese subjects** 11 th European Congress on Obesity. 30 May -2 June 2001 , Vienna Austria
48. Sermez Y , **Fidan G**, Sabir N ,Oruç N. **The efficacy of 6-month sibutramine treatment on weight loss, body distribution and total body fat in obese women** 11 th European Congress on Obesity. 30 May -2 June 2001, Vienna Austria
49. Sermez Y , **Fidan G**, Oruç N, Erciyas F, Sabir N. **The effects of insulin resistance , total body fat and boy fat distrıbution on serum Lp(a) concentration in obese female subjects** 23 rd Congress of Endocrinology and Metabolic Diseases of Turkey Joint Meeting with the European Federation of Endocrine Societies. September 7-9 2000, Ankara Turkey
50. Sermez Y , Sabir N, **Fidan G**, , Oruç N, Türk T. **The effects of short-term administiration of sibutramine on body fat distrıbution** 10 th European Congress Obesity 24-27 May 2000, Antwerb , Belgıum
51. Sermez Y , Erciyas F, **Fidan G,** Oruç N, Sabir N . **Relationship of body fat distribution with ceruloplasmin in obese women**. 10 th European Congress Obesity 24-27 May 2000, Antwerb , Belgıum
52. **Fidan G,** Sermez Y, Sabir N, Oruç N, Türk T . **Effects of insulin resistance and obesity on liver and gallbladder pathology.** 10 th European Congress Obesity 24-27 May 2000, Antwerb , Belgıum
53. Sermez Y , **Fidan G,** Erciyas F, Sabir N, Oruç N, Türk T. **Serum levels of antithrombin III in premenenopausal obese women** 10 th European Congress Obesity 24-27 May 2000, Antwerb , Belgıum

**BOOK CHAPTERS**

**C1. Güzin Fidan Yaylalı** Vitamin D and gestational diabetes Mellitus In. Aydin H, editör. Gestational diabetes. New York: Nova Science Publishers; 2020. 125-135

**C2 Güzin Fidan Yaylalı** Denge Bozukluğuna Yol Açan Metabolik ve Endokrinolojik Hastalıklar In: Ardıç FN, editör. Vertigo. İzmir: US Akademi; 2019. 541-546

**C3.** Prof. Dr. Ahmet ÇORAKÇI Prof. Dr. Ahmet KAYA Prof. Dr. Alparslan TUZCU Prof.

 Dr. Ayşegül ATMACA Prof. Dr. Emel ÖZER Prof. Dr. Emine AKAL YILDIZ Prof. Dr.

 Ersin AKARSU Prof. Dr. Esra YILDIZ Prof. Dr. Fahri BAYRAM Prof. Dr. Fırat

 BAYRAKTAR Prof. Dr. Füsun SAYGILI Prof. **Dr. Güzin Fidan YAYLALI** Prof. Dr.

 Habib BİLEN Prof. Dr. Hasan İLKOVA Prof. Dr. İbrahim ŞAHİN Prof. Dr. İlhan

 YETKİN Prof. Dr. Kamile GÜL Prof. Dr. M. Kemal BALCI Prof. Dr. M. Temel YILMAZ

 Prof. Dr. Mehmet SARGIN Prof. Dr. Murat YILMAZ Prof. Dr. Müjde AKTÜRK Prof. Dr.

 Neslihan TÜTÜNCÜ Prof. Dr. Oğuzhan DEYNELİ Prof. Dr. Ömer AZAL Prof. Dr.

 Ramazan SARI Prof. Dr. Ramis ÇOLAK Prof. Dr. Reyhan ERSOY Prof. Dr. Rıfat

 EMRAL Prof. Dr. Selçuk DAĞDELEN Prof. Dr. Sevim GÜLLÜ Prof. Dr. Sibel

 GÜLDİKEN Prof. Dr. Şehnaz KARADENİZ mProf. Dr. Taner BAYRAKTAROĞLU

 Prof. Dr. Tomris ERBAŞ Dr. Öğr. Üyesi Zafer PEKKOLAY Prof. Dr. Zeynep OŞAR

 SİVA Doç. Dr. Didem ÖZDEMİR Doç. Dr. Eren GÜRKAN Doç. Dr. Mustafa

 KULAKSIZOĞLU mDoç. Dr. Okan BAKINER Doç. Dr. Ramazan GEN Doç. Dr. Rıfkı

 ÜÇLER Tıbbi Beslenme Tedavisi ve Egzersiz Armoni Nüans Baskı Sanatları AŞ; 2019 .

 54-72

 **C4. Güzin Fidan Yaylalı,** Yalın Tolga Yaylalı**.** Testosterone Therapy and the

 Heart. Endocrinology / Book 3. October 21, 2011; 79-90.

 **C5.** Çobankara V, **Fidan G**. Sarkoidoz ve Tedavisi. Romatizmal Hastalıklar Tedavi El

 Kitabı. Ed Karaaslan Y, Öksel F. MD Yayıncılık , Ankara : 2003;201-206

**LOCAL PUBLICATIONS**

1. **Fidan Yaylalı G.** **Fonksiyonel adrenal adenomların cerrahiye hazırlanması**.

 Güney E, editör. Adrenal Adenomlar. 1. Baskı. Ankara: Türkiye Klinikleri; 2019.

 p.72-6.

1. **Fidan Yaylalı G**. Yaylalı T. **Obezite ve Kalp**. Turkiye Klinikleri J Endocrin-

 Special Topics 2013;6(1) , 45-49

1. **Yaylalı GF** ,H Kanyılmaz, G Gokce, Yaylalı YT, Alkış E **Awareness of diabetes**

 **complications in diabetic patients attending to a state hospital** Endokrinolojide

 Yönelişler 2011; 20(2): 50-56

1. Yaylalı O, Kıraç. FS, **Yaylalı G**, Yüksel D, Yılmaz M, Akdağ B. **Hipotirodi**

 **Hastalarında Hepatobiliyer Sistem Motor Fonksiyonlarının Değerlendirilmesi**

 Endokrinolojide Diyalog 2009; 6: 95-99

1. **Fidan Yaylali G,**  Yaylalı O, Kabay B, Herekli D, Akin F. **Double Parathyroid**

 **Adenoma; One in the neck, one in the Mediastinum; With Brown Tumors**

Endokrinolojide Yönelişler 2010; 19(1): 22-26

1. Akin F, **Yaylali GF**, Bastemir M. **A Type 2 Diabetes Case: The Effect Of**

 **Lipotoxicity On Beta cell Function ‘Case Report’.** Diabet Bilimi 2007;5(2):47-49

1. Fenkci MS, Sermez Y, **Yaylalı G** **Our Long Term Experimentation with Slow**

 **Release Octreotide Therapy in our Acromegalic Patients and Anusual Side**

 **Effect: Hypoglycemia** Turkish Journal of Endocrinology and Metabolism, (2005) 3

 : 89-93

1. Fenkci MS ,**Yaylalı G** ,Güçlü A, Topsakal Ş, Sermez Y,**Two Cases with**

 **Nonautoimmune Type 1Diabetes Resembling to Fulminant Diabetes** Turkish

Journal of Endocrinology and Metabolism, (2005) 2 : 65 – 67

1. **Fidan G,** Sermez Y, Sabir N, Oruç N, Türk T.**İnsülin direnci ve obezitenin**

 **karaciğer ve safra kesesi patolojilerinde etkisi.** Türk Diyabet Yıllığı 2000-2001:

281-288

1. Sermez Y, **Fidan G**, Oruç N, Erciyas F, Sabir N, Türk T .**Premenopozal**

 **kadınlarda serum antitrombin III düzeyleri**. Türk Diyabet Yıllığı 2000-2001:

262-270

E. **LOCAL ORAL AND POSTER PRESENTATIONS**

1. Cem Haymana, Alper Sönmez, İbrahim Demirci1, Güzin Fidan Yaylalı3, İrfan Nuhoğlu4, Seda Sancak5, Murat Yılmaz6, Yüksel Altuntaş7, Nevin Dinçağ8, Tevfik Sabuncu9, Fahri Bayram10, İlhan Satman8, Temd Çalışma Grubu11 **Türkiye’de Tip 2 Diyabet hastalarının oral ve enjektabl ilaç kullanım oranları ile klinik ve sosyodemografik özellikleri arasındaki ilişki; TemD TeDavi çalışması** 41.Türkiye Endokrinoloji ve Metabolizma Hastalıkları Kongresi: 27 Nisan – 1 Mayıs Mayıs 2019, Antalya ( sözlü bildiri)
2. Çağlar Keskin, Özgür Demir, Alper Çağrı Karcı, Dilek Berker, Zeynep Cantürk, Güzin Fidan Yaylalı, Şenay Topsakal, Reyhan Ersoy, Fahri Bayram, Melek Eda Ertörer, Emre Bozkırlı, Filiz Haydardedeoğlu, Esra Nur Ademoğlu Dilekçi, Seyid Ahmet Ay, Güven Barış Cansu1, Mustafa Şahin, Rıfat Emral, Demet Çorapçıoğlu **Akromegali hastalarında uzun Dönem Tedavi sonuçları: 10 farklı merkezde Takip edilen 547 akromegali hastasının verilerinin değerlendirilmesi** 41.Türkiye Endokrinoloji ve Metabolizma Hastalıkları Kongresi: 27 Nisan – 1 Mayıs Mayıs 2019, Antalya ( sözlü bildiri)
3. Semin Melahat Fenkçi,,Erhan Kaçmaz, Veysel Erol,Sema Taban, Şenay Topsakal, **Güzin Fidan Yaylalı**. **İntensif insülin kullanan obez Tip2 diyabetli olgularda Decludec/İnsülin Aspart koformulasyonunun etkileri** 54. Ulusal Diyabet Kongresi , 18-22 Nisan 2018, Beldibi Antalya
4. Kılıc Toprak E, **Fidan Yaylalı G**, Ozdemir Y, Topsakal S, Kılıc Erkek Ö, Oymak B, Bor Küçükatay M. **Akromegali hastalarında hemoreolojik değişiklikler** 43. Ulusal Fizyoloji Kongresi:7-10 Eylül 2017 , Denizli ( sözlü bildiri)
5. Gurkan H, Celik M, **Fidan Yaylalı G**, Algün E, Çalışkan M, Omma T, Yıldırım R, Ünal E, Yılmaz Bülbül B, Ulusal S.**Türk HastalardaTHRB geninin analizi ve 3 yeni patojenik varyantın tanımı**. 2. Ege Endokrin Hastalıkları ve Genetik Sempozyumu :23-25.02. 2017 ( sözlü bildiri)
6. Akinci B, Onay H, Demir T, Savas-Erdeve Ş, Gen R, Simsir IY, Keskin FE, Erturk MS, Uzum AK, **Yaylali GF**, Ozdemir NK, Atik T, Ozen S, Yurekli BS, Apaydin T, Altay C, Akinci G, Demir L, Comlekci A, Secil M, Oral EA. **Familyal parsiyel lipodistrofilerde klinik prezentasyonlar, metabolik anormallikler ve son organ komplikasyonları .**39.Türkiye Endokrinoloji ve Metabolizma Hastalıkları Kongresi: 3-7 Mayıs 2017, Antalya ( sözlü bildiri)
7. Fenkci SM, Topsakal S, **Fidan Yaylalı G**, Senol H. Tip 2 **Diyabet Hastalarında exanatid tedavisinin minimental test sonuçlarına etkisi.** 39.Türkiye Endokrinoloji ve Metabolizma Hastalıkları Kongresi: 3-7 Mayıs 2017, Antalya
8. Şenay Topsakal, **Güzin F Yaylalı**, Fulya Akın, Özen Dedeoğlu, Mehmet

 Sercan Ertürk, **Evaluation of The Realtionship Android Obesity and Plasma**

 **TNF-α, IL-6, CRP and Fibrinogen Levels,** 12. Metabolik Sendrom

 Sempozyumu: 3-6 Eylül 2015 , Bodrum

1. Güleryüz B, Akin F, **Fidan Yaylali G,** Topsakal Ş, Tunc- Ata M, Mergen

 Dalyanoğlu M, Turgut S **Hashimoto tiroiditli hastalarımızda vitamin düzeyi**

37.Türkiye Endokrinoloji ve Metabolizma Hastalıkları Kongresi: 6-10 Mayıs

 2015, Antalya

1. Dedeoğlu Ö, **Fidan Yaylalı G**, Çetin A, Şenol H, Akın F, Topsakal Ş, Ertürk

 MS.**Obezlerde vücut yağ dağılımı ile oksidatif stres belirteçleri arsındaki ilişki**

37.Türkiye Endokrinoloji ve Metabolizma Hastalıkları Kongresi: 6-10 Mayıs

 2015, Antalya

1. Gököz Doğu G, **Fidan Yaylalı G**, Yapar Taşköylü B, Demiray G , Yaren A

 **Megesterol asetat tedavisinde adrenal yetmezlik gelişimi: Tek merkez deneyimi**

XI. Ulusal Tıbbi Onkoloji Kongresi: 17- 21 Eylül 2014, Kuzey Kıbrıs Türk

 Cumhuriyeti

1. Dedeoğlu Ö, Yılmaz H, Ertürk MS, **Fidan Yaylalı G**,Akın F **Propisile sekonder toksik hepatit ve Gravesde kortikosteroid ve lityum tedavisinin yeterli olmadığı hastalarda plazmaferez sonrası tiroidektomi** 36.Türkiye Endokrinoloji ve Metabolizma Hastalıkları Kongresi: 21-25 Mayıs 2014, Antalya
2. Topsakal S, Akın F, **Yaylali GF Obez kadınlarda mikroalbüminüri ve**

 **hormon profili ile ilşkisi** 35.Türkiye Endokrinoloji ve Metabolizma

 Hastalıkları Kongresi: 15-19 Mayıs 2013, Antalya

1. Tural M, **Fidan Yaylalı G**, Akin F, Yerlikaya E **Hiperaldosteronizmli olguda saptanan adrenokortikal tümör** 35.Türkiye Endokrinoloji ve Metabolizma Hastalıkları Kongresi: 15-19 Mayıs 2013, Antalya
2. Topsakal S, Akın F, **Yaylali GF,** Yerlikaya E **Tiroid nodüllü akromegalik**

 **hastalarda serum leptin düzeyleri** 34. Türkiye Endokrinoloji ve Metabolizma

 Hastalıkları Kongresi: 11-15 Nisan 2012, Antalya

1. Gurbulak S, **Fidan Yaylalı G**, Yerlikaya E. Akin F. Topsakal S, Tanrıverdi H, Akdag B, Aslan AR **Akromegali hastalarında resistin, leptin ve ekokardiografik bulgularla ilişkileri** 33.Türkiye Endokrinoloji ve Metabolizma Hastalıkları Kongresi: 12-16 Ekim 2011, Antalya
2. Akin F, **Yaylali GF,** Fenkçi S **Lanreotid ile primer medikal tedavide tümör küçülmesi** 31. Türkiye Endokrinoloji ve Metabolizma Hastalıkları Kongresi: 15-16 Ekim 2008, Antalya
3. Akin F, Bastemir M**, Yaylali GF,** Alkis E**,** Kaptanoglu B **Subklinik hipertiroidili hastalarda GH/IGF-1 aksı.** 31. Türkiye Endokrinoloji ve Metabolizma Hastalıkları Kongresi: 15-16 Ekim 2008, Antalya
4. Akin F, **Yaylali GF,** Yüksel S, Alkış E, Fenkcı S **Denizli il merkezinde tip 2**

 **diyabetik hastalarda tedavide neredeyiz?** 44.Ulusal Diyabet Kongresi 28 Mayıs-1

Haziran 2008, Antalya ( sözlü bildiri)

1. Akin F, **Yaylali GF,** Akalın Ş, Turgut S, Fenkcı S **Diyabetik ayak tanılı**

 **hastalarımızın klinik değerlendirilmesi: Pamukkale Üniversitesi deneyimi** 44.

 Ulusal Diyabet Kongresi 28 Mayıs-1 Haziran 2008, Antalya

1. Akin F, **Yaylali GF,** Yüksel S, Alkış E Fenkcı S **Denizli il merkezinde tip 2**

 **diyabetik hastalarda gözlenen komplikasyonlar ve eşlik eden hastalıklar**

44. Ulusal Diyabet Kongresi 28 Mayıs-1 Haziran 2008, Antalya ( sözlü bildiri)

1. **Yaylali GF**, Akin F, Bastemir M., Yaylali YT, Ozden A **Subklinik Cushing**

 **sendromu ve mikroadenomla birlikte feokromositoma.** 30. Türkiye

 Endokrinoloji ve Metabolizma Hastalıkları Kongresi: 24-28 Ekim 2007, Antalya

1. Baştemir M , Turgut S, Akın F, Turgut G, Kursunluoğlu R , **Fidan Yaylalı G,**

 **Otoimmun tiroid hastalığında ACE gen polimorfizmi** 30. Türkiye Endokrinoloji

ve Metabolizma Hastalıkları Kongresi: 24-28 Ekim 2007, Antalya

1. Akin F, **Yaylali GF**, Bastemir M. **Hipertiroidi hastalarında Cerrahi ve**

 **Radyoaktif Iyot öncesi Lityum Kullanımı.** 30. Türkiye Endokrinoloji ve

Metabolizma Hastalıkları Kongresi: 24-28 Ekim 2007, Antalya

1. **Yaylalı GF**, Akın F, Semerci N, Düzcan F. **46XX Seks Reversal Sendromlu**

 **Bir Vakamız.** 30. Türkiye Endokrinoloji ve Metabolizma Hastalıkları Kongresi:

24-28 Ekim 2007, Antalya

1. Akın F, Turgut S, Bastemir M, Turgut G, Kurşunluoğlu R, Karasu U, **Yaylalı GF.**

 **İnsülin direnci ve ACE gen polimorfizmi**. 30. Türkiye Endokrinoloji ve

Metabolizma Hastalıkları Kongresi: 24-28 Ekim 2007, Antalya

1. Akın F., Bastemir M, **Yaylalı GF,** Alkıs E, Kaptanoglu B**. Subklinik**

 **Hipotiroidide Growth hormone/İnsülin like Growth Factor-1 Aksı.** 30.

Türkiye Endokrinoloji ve Metabolizma Hastalıkları Kongresi: 24-28 Ekim 2007,

 Antalya

1. **Yaylalı GF.,** Akın F., Bastemir M. **Tip 2 Diabet vakası: Ciddi lipotoksisitenin**

 **beta hücre fonksiyonuna etkisi.** 29. Türkiye Endokrinoloji ve Metabolizma

Hastalıkları Kongresi: 6-10 Eylül 2006, Antalya.

1. Baştemir M**,** **Yaylalı GF**, Akın F, Alkış E, Karasu U. **Diabetik hastalarda**

 **hipertansiyon sıklığı ve mikrovasküler komplikasyonlarla ilişkisi.** 42.Ulusal

 Diyabet Kongresi: 10-14 mayıs 2006, Antalya

1. Akın F., Baştemir M.**,** **Yaylalı GF**, Alkış E., Akdam H. **Diyabetik hastalarda**

 **farklı tedavi gruplarında komplikasyonların değerlendirilmesi.** 42.Ulusal

Diyabet Kongresi: 10-14 mayıs 2006, Antalya

1. **Yaylalı GF**, Akın F, Baştemir M, Alkış E, Karasu U. **Diabet polikliniğimizde**

 **izlenen hastaların retrospektif değerlendirilmesi.**42.Ulusal Diyabet Kongresi:

10-14 mayıs 2006, Antalya

1. Fenkçi S, Sermez Y, **Fidan Yaylalı G** **Somatostatin alan akromegalili**

 **olgularımızın Değerlendirilmesi**27. Türkiye Endokrinoloji ve Metabolizma

Hastalıkları Kongresi, İstanbul18-22 Eylül 2004.

1. Sermez Y, , Fenkçi S, **Fidan Yaylalı G** , Sabir N ,Özdeş İ **Otoimmün hastalığı**

 **olan 260 olgu** 27. Türkiye Endokrinoloji ve Metabolizma Hastalıkları Kongresi,

 İstanbul18-22 Eylül 2004.

1. Sermez Y, **Fidan G**, Fenkçi S, Özdeş İ, Sabir N, Kaptanoğlu B **Obezlerde**

 **sibutramine sağaltımının total vücut yağı , vücut yağ dağılımı ve metabolik**

 **parametrelere etkisi** II. Türk Obezite Kongresi ve I. Beslenme Sempozyumu. 07-

11 Nisan 2004 , Denizli , Turkey

1. Çobankara V, **Fidan G**, Kaleli İ. Çolakoğlu M. **SLE Tedavisi sırasında gelişen**

 **tüberküloz meningoensefaliti** Ulusal Romatoloji Kongresi 2002. 1-5 Ekim 2002,

1. Çobankara V, **Fidan G,** Çolakoğlu M , Yılmaz M. **Denizli Bölgesinde Ailesel**

 **Akdeniz Ateşi Prevelansı** Ulusal Romatoloji Kongresi 2002. 1-5 Ekim 2002

1. Sermez Y , **Fidan G**, Sabir N ,Oruç N. **Obez kadınlarda 6 aylık sibutramin**

 **tedavisinin kilo kaybı ve vücut dağılımı üzerine etkisi** I. Ulusal Obezite

 Kongresi 8-10 Nisan 2001, İstanbul, Türkiye

1. Sermez Y , **Fidan G**, Oruç N, Sabir N, Erciyas F. **Obezlerde kilo kaybı**

 **sonrasında serum antitrombin III düzeylerinde değişiklikler** I. Ulusal Obezite

 Kongresi 8-10 Nisan 2001 ,İstanbul, Türkiye

1. **Fidan G**, Sermez Y, Sabir N, Oruç N, Türk T . **Effects of insulin resistance and**

 **obesity on liver and gallbladder pathology.** ( **ikincilik ödülü**) XXXVI. Ulusal

diabet kongresi ve V. Uluslar arası katılımlı obezite Sempozyumu 14-19 Mayıs

 2000, Gaziantep, Türkiye

1. Sermez Y , **Fidan G,** Erciyas F, Sabir N, Oruç N, Türk T. **Serum levels of**

 **antithrombin III in premenenopausal obese women** XXXVI. Ulusal diabet

 kongresi ve V. Uluslar arası katılımlı obezite Sempozyumu 14-19 Mayıs 2000,

 Gaziantep, Türkiye

1. Sermez Y , Sabir N , **Fidan G,** , Oruç N, Türk T. **The effects of short-term**

 **administiration of sibutramine on body fat distrıbution** XXXVI. Ulusal diabet

 kongresi ve V. Uluslar arası katılımlı obezite Sempozyumu 14-19 Mayıs 2000,

 Gaziantep, Türkiye

1. Sermez Y , Erciyas F, **Fidan G**, Oruç N, Sabir N . **Relationship of body fat**

 **distribution with ceruloplasmin in obese women.** XXXVI. Ulusal diabet

kongresi ve V. Uluslar arası katılımlı obezite Sempozyumu 14-19 Mayıs 2000,

 Gaziantep, Türkiye